Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patientswith diabetes

Diabetes Care

Volumn 36, Issue 12, 2013, Pages 3953-3960

  Habel, Laurel A ^a   Danforth, Kim N ^b   Quesenberry, Charles P ^a   Capra, Angela ^a   Van Den Eeden, Stephen K ^a   Weiss, Noel S ^c   Ferrara, Assiamira ^a  

^a DIVISION OF RESEARCH   (United States)

^b Kaiser Permanente Southern California ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; TREATMENT DURATION; ADOLESCENT; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; TIME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CALIFORNIA; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; RISK ASSESSMENT; TIME FACTORS; YOUNG ADULT;

EID: 84891859969     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0140     Document Type: Article

References (17)

1. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-1744
2. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a populationbased follow-up study in Sweden. Diabetologia 2009;52:1745-1754
3. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52: 1755-1765
4. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
5. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-1123
6. Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011;54:2254-2262
7. Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of breast cancer-a four-year population-based observation. Acta Oncol 2012;51:400-402
8. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012;55:644-653
9. Lind M, Fahlén M, Eliasson B, Odén A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 2012;6:53-59
10. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011;34:1965-1971
11. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010; 33:1997-2003
12. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012;55: 51-62
13. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patientsda nationwide cohort study. PLoS ONE 2011;6:e21368
14. Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a three-year population-based observation. Acta Oncol 2011;50:685-693
15. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-2506
16. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367: 319-328
17. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203